STA Research assigned Purple Biotech with a Speculative Buy rating, with a 12 month target forecast of $4 per share.
Based on the Purple Biotech stock forecasts from 2 analysts, the average analyst target price for Purple Biotech stock is $14.50 over the next 12 months. Purple Biotech stock’s average analyst rating is Buy. Stock Target Advisor’s own stock analysis of Purple Biotech stock is Very Bearish, based on 0 positive and 3 negative signals. At the last closing, Purple Biotech’s stock price was USD 2.17. Purple Biotech’s stock price has changed by -0.04% over the past week, -0.36% over the past month and -51.35% over the last year.
What we like:
There is no fundamental attribute that we can detect on the stock that would warrant a positive outlook. The stock is a pure speculative play!
What we don’t like:
Poor risk-adjusted returns
This company is delivering below median risk-adjusted returns to its peers. Even if it is outperforming on returns, the returns are unpredictable. Proceed with caution.
The total returns for this company are volatile and above the median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.